Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase NA 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 18Thoracic 13Gastrointestinal 12Genitourinary 9Lymphoid 5Head & Neck 5Gynecologic 5Other hematologic neoplasm 4Other solid neoplasm 3Plasma cell 2Endocrine 2Classical hematology 2Dermatologic 1

Conditions

Thyroid Cancer, Papillary 1Pituitary Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Adenocarcinoma, Follicular 1Acromegaly 1

Interventions

Everolimus 8lanreotide 7Octreotide 7lutetium Lu 177 dotatate 6pasireotide 5Thyrotropin Alfa 5Mitotane 4Etoposide 4Doxorubicin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4amino-acid, glucose, and electrolyte solution 3Mifepristone 3Filgrastim 3Corlux 3Cisplatin 3Chemotherapy, Adjuvant 3Capecitabine 3Cabergoline 3vandetanib 2telotristat ethyl 2surufatinib 2ribociclib 2fluorodopa F 18 2cabozantinib 2Temozolomide 2Receptor-Like Protein Tyrosine Phosphatases, Class 2 2Lutetium-177 2Lutetium 2Leucovorin 2Iodine-131 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Injections × Endocrine × Clear all
NCT03439709 2018-03-01

MERGE

Samsung Medical Center

Phase 3 Unknown
90 enrolled
Endocrine

Acromegaly, Pituitary Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT00295763 2015-03-18

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

Sanofi

Phase 3 Completed
61 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡